Pharmacists' Role in Enhancing CIDP Treatment Adherence and Innovations

In an era marked by rapid advancements in medical therapeutics, the role of pharmacists in promoting medication adherence, particularly for chronic inflammatory demyelinating neuropathy (CIDP), has become increasingly vital. Amy Duong, PharmD, BCACP, an ambulatory care clinical pharmacist at Yale New Haven Health, emphasized the necessity of comprehensive patient education and logistical support in a recent interview with Pharmacy Times®.

CIDP is a rare neurological disorder characterized by progressive weakness and sensory loss due to nerve inflammation. Effective management is crucial for improving patient outcomes, yet adherence to medication regimens presents challenges. According to Duong, early and ongoing education is fundamental. "Helping patients understand the mechanisms of their therapies, what improvements to expect, and the timelines associated with clinical trial data are key components of ensuring adherence," she stated.

Pharmacists are uniquely positioned to address barriers to medication adherence. They can troubleshoot issues related to insurance and scheduling, which often impede treatment continuity. For instance, Duong explained that if a patient's infusion appointment is canceled, pharmacists investigate potential underlying causes, such as transportation issues or insurance challenges. This proactive approach is essential to prevent lapses in treatment.

Emerging therapies for CIDP have also transformed the treatment landscape. The recent approval of efgartigimod alfa and hyaluronidase-qvfc in July 2024 has introduced a new mechanism targeting the neonatal Fc receptor pathway, offering patients an alternative treatment modality. In April 2025, a prefilled syringe formulation of this treatment was approved, allowing patients to self-administer their medication, thereby reducing the logistical burdens associated with infusion appointments.

Duong highlighted the importance of pharmacists staying informed about these developments. "I encourage pharmacists to engage with professional meetings and consult trusted resources, such as the GBS/CIDP Foundation, to stay updated on new therapies and clinical trials," she said. Collaborating with clinical pharmacy teams to assess which patients would benefit from new treatments and ensuring a smooth implementation process is crucial for optimizing patient care.

The implications of these advancements are profound. Enhanced medication adherence not only improves individual patient outcomes but also reduces overall healthcare costs associated with complications from poorly managed CIDP. As the healthcare landscape evolves, the integral role of pharmacists in managing chronic conditions will become even more pronounced, underscoring the necessity for ongoing education and adaptation to emerging treatment paradigms.

By fostering a comprehensive approach to patient education and treatment management, pharmacists can significantly enhance adherence rates and improve the quality of care for patients living with CIDP. As the field continues to evolve, the proactive involvement of pharmacists will be essential in navigating the complexities of new therapies and ensuring optimal patient outcomes.